HC Wainwright reaffirmed their neutral rating on shares of Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) in a research report report published on Monday morning, Zacks.com reports.
Trillium Therapeutics has a 1-year low of C$28.50 and a 1-year high of C$39.45.
Trillium Therapeutics Company Profile
Featured Story: What are no-load funds?
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.